M. Turner

发表

Biosimilar granulocyte–colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?

H. Bonig, P. Becker, A. Schwebig, 2014, Transfusion.

Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience

O. Heine, A. Lorenz, M. Turner, 2014, Journal of blood medicine.

Clinical experience with Zarzio® in Europe: what have we learned?

H. Tesch, P. Gascón, N. Wilking, 2013, Supportive Care in Cancer.

A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study

G. London, L. Gesualdo, C. Combe, 2013, Internal and Emergency Medicine.

Promoting evidence-based management of anemia in cancer patients: background, development, and scientific validation of RESPOND, a web-based clinical guidance system based on the EORTC guidelines.

M. Aapro, I. Abraham, M. Muenzberg, 2008, Critical reviews in oncology/hematology.

Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

C. Bokemeyer, M. Boccadoro, M. Aapro, 2016, Supportive Care in Cancer.

The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines

C. Bokemeyer, M. Aapro, H. Ludwig, 2008, Supportive Care in Cancer.

Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim.

M. Aapro, P. Gascón, H. Ludwig, 2011, Critical reviews in oncology/hematology.

Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study.

C. Bokemeyer, M. Aapro, T. Albrecht, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments.

M. Boccadoro, M. Aapro, P. Gascón, 2011, Critical reviews in oncology/hematology.

Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study.

C. Bokemeyer, M. Aapro, T. Albrecht, 2009, European journal of cancer.

Intraclass correlation metrics for the accuracy of algorithmic definitions in a computerized decision support system for supportive cancer care

C. Bokemeyer, M. Aapro, J. Foubert, 2007, Supportive Care in Cancer.

Prevention and Treatment of Chemotherapy-Induced Neutropenia with the Biosimilar Filgrastim: A Non-Interventional Observational Study of Clinical Practice Patterns

H. Tesch, T. Ulshöfer, M. Turner, 2015, Oncology Research and Treatment.

Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study)

G. London, L. Gesualdo, C. Combe, 2015, International Urology and Nephrology.

Promoting evidence-based management of anemia in cancer patients: concurrent and discriminant validity of RESPOND, a web-based clinical guidance system based on the EORTC guidelines for supportive care in cancer

Ivo Abraham, Pierre Soubeyran, Matti Aapro, 2010, Supportive Care in Cancer.

Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: initial evidence from the RESPOND study.

M. Aapro, T. Albrecht, I. Abraham, 2009, European journal of cancer.

Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective

Hillel P. Cohen, Dorothy McCabe, G. Woollett, 2023, BioDrugs.

Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain

V. Falcó, A. Rivero, S. Moreno, 2023, Infectious Diseases and Therapy.